Tag: approval

REGINA, Saskatchewan, June 26, 2026 (GLOBE NEWSWIRE) -- Information Services Corporation (TSX:ISC) (“ISC” or the “Company”) is pleased to announce that, at the special meeting (the “Meeting”) of shareholders held earlier today, ISC shareholders (“Shareholders”) voted in favour of the special resolution (the “Arrangement Resolution”) approving the previously announced plan of arrangement (the “Transaction”) under The Business Corporations Act, 2021 (Saskatchewan) (the “SBCA”), pursuant to which a wholly-owned subsidiary of Plenary Americas LP (“Plenary Americas”) will acquire all of the issued and outstanding Class A Limited Voting Shares (the “Shares”) of ISC at a price per Share of CAD$51.00 (other than those Shares held by certain members of ISC’s senior management who have entered into equity rollover agreements to retain an interest in ISC following closing of the Transaction in respect of the Shares owned by them (the “Rollover Shareholders”)).

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- WeRide Inc. (“WeRide” or the “Company”) (NASDAQ: WRD; HKEX: 0800), a global leader in autonomous driving technology, today announced that each of the proposed resolutions submitted for shareholders’ approval (the “Proposed Resolutions”) as set forth in the notice of the annual general meeting dated May 8, 2026, Beijing time (the “AGM Notice”), has been adopted at the annual general meeting held in Guangzhou, Guangdong Province, China today.

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000^® Index, the large-cap Russell 1000^® Index, the small-to-mid-cap Russell 2500^® Index, and the Russell Midcap^® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.